ADMA Biologics, Inc. (ADMA)

In the past six months, ADMA Biologics' stock price has been impacted by several key events. A short-seller report in March 2026 led to a stock decline and securities fraud investigations, which the company refuted. In May 2026, Q1 earnings missed revenue estimates, leading to a lowered full-year forecast and stock decline. Also in May 2026, the FDA approved a label expansion for ASCENIV™ to include pediatric patients. In April 2025, ADMA received FDA approval for a production yield enhancement process.

Based on available information, there is no explicit mention of significant demand seasonality for ADMA Biologics' products and services. The company's financial outlook and reports frequently highlight consistent demand for its immune globulin products.

ADMA Biologics, Inc. is a biopharmaceutical company focused on manufacturing, marketing, and developing specialty plasma-derived biologics for immunodeficient patients and those susceptible to infectious diseases. The company's major FDA-approved products include BIVIGAM® for primary humoral immunodeficiency, ASCENIV™ also for PI treatment, and NABI-HB® for enhanced immunity against hepatitis B. ADMA operates FDA-approved source plasma collection facilities and is developing SG-001, a preclinical investigative hyperimmune globulin.

ADMA Biologics primarily operates within the United States, with its headquarters in Ramsey, New Jersey, and its primary manufacturing site in Boca Raton, Florida. The company also maintains various plasma collection centers across the U.S. ADMA emphasizes its entirely U.S.-based, end-to-end operations to provide supply chain resilience.

ADMA Biologics' brand reputation has been significantly affected by a short-seller report alleging financial improprieties, leading to a stock price decline and investigations. The company has actively refuted these claims, emphasizing its commitment to transparent financial reporting.

ADMA Biologics' ownership structure includes institutional, retail, and individual investors. Institutional investors hold a significant portion of the company's stock, with major holders including BlackRock, Inc., Vanguard Group Inc, State Street Corp, Invesco Ltd., Sachem Head Capital Management LP, and Westfield Capital Management Co Lp. Individual insider ownership is also present.